1 Hyperphosphatemia is probably the most worrisome feature of cinacalcet use in patients with stage 3–4 CKD. High serum phosphorus level has been implicated as one of the main contributors to ...

Might some physicians have been more motivated or attentive in treating hyperphosphatemia and/or ... even among patients with stage 4 CKD. However, given its observational nature, the role of ...

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025. If approved, OLC has the potential to meaningfully improve the treatment burden for hyperphosphatemia ...

Karnataka: Shilpa Medicare CDMO partner Unicycive Therapeutics, Inc. has announced that the U.S. Food and Drug Administration ...

Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update. Shandong Xinhua Pharmaceutical ...

Unicycive, which is seeking an FDA green light for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis, Monday said the agency set a target ...

If approved, OLC has the potential to meaningfully improve the treatment burden for hyperphosphatemia patients with chronic kidney disease (CKD) on dialysis. “We are thrilled with the FDA ...

multidose study in adult patients with CKD with hyperphosphatemia receiving maintenance hemodialysis. The aim of the study was to assess the tolerability and safety of OLC at doses that achieve ...

As a result, hyperphosphatemia is a nearly universal condition among people with CKD on maintenance dialysis, with internationally recognized KDIGO treatment guidelines that recommend lowering ...

“If approved, we believe OLC’s high potency and low pill burden would provide a best-in-class option for patients with ...

Unicycive Therapeutics (UNCY) announced that the U.S. Food and Drug Administration, FDA, has accepted the New Drug Application, NDA, for ...

entitled “Sustained Phosphate Reduction Assessed by P AUC With Tenapanor Is Associated With Reduced Fibroblast Growth Factor 23 in Patients With Chronic Kidney Disease and Hyperphosphatemia on ...